Terry Hyslop Selected Research

Enterotoxin Receptors

2/2013	Guanylyl cyclase C as a biomarker in colorectal cancer.
1/2013	Molecular staging of node negative patients with colorectal cancer.
5/2011	Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer.
12/2007	Relative quantification based on logistic models for individual polymerase chain reactions.
4/2007	Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer.
12/2006	Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells.
8/2006	A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer.
1/2006	Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction.
12/2005	The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas.
9/2005	Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Terry Hyslop Research Topics

Disease

69	Neoplasms (Cancer) 01/2022 - 08/2003
37	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2008
21	Colorectal Neoplasms (Colorectal Cancer) 12/2020 - 09/2005
12	Prostatic Neoplasms (Prostate Cancer) 01/2021 - 01/2010
10	Neoplasm Metastasis (Metastasis) 12/2018 - 08/2006
6	Noninfiltrating Intraductal Carcinoma (DCIS) 01/2020 - 06/2004
6	Carcinogenesis 11/2014 - 09/2007
5	Pathologic Complete Response 01/2022 - 10/2018
4	Papillary Thyroid Cancer 11/2019 - 01/2015
4	Lymphatic Metastasis 07/2015 - 02/2009
4	Adenocarcinoma 02/2014 - 08/2009
3	Thyroid Neoplasms (Thyroid Cancer) 11/2019 - 01/2017
3	Colonic Neoplasms (Colon Cancer) 01/2019 - 09/2007
3	Melanoma (Melanoma, Malignant) 01/2018 - 01/2012
2	Circulating Neoplastic Cells 01/2021 - 01/2018
2	Erectile Dysfunction 03/2015 - 01/2015
2	Glioma (Gliomas) 02/2013 - 06/2010
2	Fistula 01/2013 - 05/2009
2	Carcinoma (Carcinomatosis) 01/2013 - 01/2010
2	Pancreatic Fistula (Pancreatic Fistulas) 01/2013 - 05/2009
2	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011 - 08/2009
2	Meningioma (Meningiomas) 05/2010 - 08/2003
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 09/2007 - 05/2007
2	Neoplasm Micrometastasis 08/2006 - 09/2005
2	Lacerations 04/2003 - 03/2002
1	Inflammation (Inflammations) 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2021
1	Inflammatory Breast Neoplasms 02/2020

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 01/2021 - 06/2004
15	Proteins (Proteins, Gene)FDA Link 01/2020 - 06/2003
10	Messenger RNA (mRNA)IBA 01/2022 - 12/2005
10	Enterotoxin ReceptorsIBA 02/2013 - 09/2005
8	Hormones (Hormone)IBA 01/2022 - 08/2003
6	MicroRNAs (MicroRNA)IBA 01/2018 - 03/2004
6	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2014 - 09/2005
5	Protein Isoforms (Isoforms)IBA 01/2020 - 06/2003
4	VaccinesIBA 01/2020 - 12/2016
4	Estrogen ReceptorsIBA 01/2020 - 09/2011
4	Tyrosine (L-Tyrosine)FDA Link 10/2016 - 06/2011
3	Epidermal Growth Factor (EGF)IBA 01/2021 - 01/2013
3	Biological ProductsIBA 01/2020 - 04/2010
3	Transcription Factors (Transcription Factor)IBA 10/2019 - 04/2010
3	LigandsIBA 10/2019 - 04/2007
3	Guanylate Cyclase (Guanylyl Cyclase)IBA 01/2018 - 02/2009
3	Estrogen Receptor Modulators (Antiestrogen)IBA 01/2013 - 06/2011
3	ErbB Receptors (EGF Receptor)IBA 07/2012 - 08/2003
3	CyclinsIBA 05/2010 - 08/2008
3	Enterotoxins (Enterotoxin)IBA 12/2006 - 09/2005
2	AntibodiesIBA 12/2020 - 01/2019
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 10/2018
2	RNA (Ribonucleic Acid)IBA 01/2020 - 08/2006
2	AntigensIBA 01/2020 - 01/2019
2	ProlactinIBA 12/2018 - 01/2013
2	Phenobarbital (Luminal)FDA Link 11/2017 - 01/2013
2	Indicators and Reagents (Reagents)IBA 07/2015 - 01/2013
2	Sorafenib (BAY 43-9006)FDA Link 02/2013 - 12/2010
2	AndrogensIBA 01/2013 - 01/2012
2	Cyclin D1IBA 05/2010 - 08/2008
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 08/2003 - 08/2003
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022
1	Carboplatin (JM8)FDA LinkGeneric 01/2022
1	Bevacizumab (Avastin)FDA Link 01/2022
1	CytokinesIBA 01/2022
1	Biological FactorsIBA 01/2022
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2022
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2022
1	Potassium Channels (Potassium Channel)IBA 11/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 11/2021
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 11/2021
1	LipidsIBA 11/2021
1	Prednisone (Sone)FDA LinkGeneric 01/2021
1	Abiraterone AcetateIBA 01/2021
1	Recombinant DNA (Recombinant DNA Research)IBA 01/2021
1	Letrozole (Femara)FDA LinkGeneric 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2020
1	Combined VaccinesIBA 01/2020
1	boldenone undecylenate (Equipoise)IBA 11/2019
1	Blocking AntibodiesIBA 10/2019
1	Humanized Monoclonal AntibodiesIBA 10/2019

Therapy/Procedure

26	Therapeutics 04/2021 - 12/2006
15	Radiotherapy 01/2020 - 08/2003
9	Drug Therapy (Chemotherapy) 01/2022 - 06/2010
7	Neoadjuvant Therapy 01/2022 - 10/2018
5	Thyroidectomy 11/2019 - 01/2015
5	Adjuvant Chemotherapy 01/2019 - 11/2009
4	Mastectomy (Mammectomy) 01/2022 - 01/2019
4	Segmental Mastectomy (Lumpectomy) 01/2022 - 11/2017
4	Aftercare (After-Treatment) 01/2020 - 02/2013
4	Lymph Node Excision (Lymph Node Dissection) 10/2019 - 01/2012
3	Pancreaticoduodenectomy 08/2009 - 02/2009
2	Length of Stay 01/2019 - 01/2013
2	Prostatectomy (Retropubic Prostatectomy) 03/2015 - 01/2015
2	Episiotomy 04/2003 - 03/2002
2	Surgical Instruments (Clip) 04/2003 - 03/2002
1	Castration 01/2021
1	Time-to-Treatment 01/2021
1	Combined Modality Therapy 02/2020
1	Immunotherapy 01/2020